Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2002-09-05
2009-06-02
Yaen, Christopher H (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100
Reexamination Certificate
active
07541141
ABSTRACT:
The present invention provides that ERRα is a breast cancer biomarker of clinical course and treatment sensitivity and, itself, a target for breast cancer treatment. A high ERRα level in breast cancer indicates poor prognosis. Analyzing ERRα expression level along with the status of ERα and ErbB2 can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by modulating ERRα activity.
REFERENCES:
patent: 5298429 (1994-03-01), Evans et al.
Ali et al., J. Mammary Gland Biology and Neoplasia, 2000, 5(3): 271-281.
Relf et al., Cancer Research, 1997, 57:963-969.
Utsumi et al., Int. J. Cancer: 2000, 89:39-43.
Suzuki et al., Cancer Res. 2004, 64: 4670-4676.
Suzuki et al., Cancer Res., 2004, 64, 4670-4676.
Beers and Berkow, Eds. The Merk Manual of Diagnosis and Therapy: 17th Edition. Merk & Co. Whitehouse Station, N.J. 1999, pp. 973-981.
Chen, S., Zhou, D., Yang, C., and Sherman, M. Molecular basis for the constitutive activity of estrogen related receptor a-1 (ERRa-1). J Biol Chem. 16: 16. 2001.
Clark, G. M. and McGuire, W. L. Prognostic factors in primary breast cancer. Breast Cancer Res Treat. 3: S69-72, 1983.
Clark, G. M., McGuire, W. L., Hubay, C. A., Pearson, O. H., and Carter, A. C. The importance of estrogen and progesterone receptor in primary breast cancer. Prog Clin Biol Res 183-190, 1983.
Dowsett, M., T. Cooke, et al. (2000) “Assessment of HER2 status in breast cancer: why, when and how?” Eur. J. Cancer 36(2): 170-6.
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun. B., Esmaeli, B., Fritsche, H. A., Sneige, N., Smith, T. L., and Hortobagyi, G. N. Phase II study of weekly docetaxel and trastuzumab . . . J Clin Oncol, 20: 1800-1808, 2002.
Giguere, V., Yang, N., Segui, P., and Evans, R. M. Identification of a new class of steroid hormone receptors. Nature, 331: 91-94, 1988.
Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., and Miles, D. W. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer, 79: 1220-1226, 1999.
Hynes, N. E. and Stern, D. F. The biology of erbB-2
eu/HER-2 and its role in cancer. Biochim Biophys Acta, 1198: 165-184, 1994.
Johnston, S.D., et al., “Estrogen-related receptor 1 functionally binds as a monomer to extended half-site sequences including ones contained within estrogen-response elements,” Mol. Endo. 11(3):342-352, 1997.
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., and Yarden, Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for mutiple stroma-derived growth factors. Proc Natl Acad Sci U S A. 96: 4995-5000, 1999.
Klapper, L. N., Kirschbaum, M. H., Sela, M., and Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res, 77: 25-79, 2000.
Kraus, R.J., et al. Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells. J Biol Chem 277: 24826-34, 2002.
Mertz, J.E., et al., “hERR1, a player in estrogen responsiveness?” Steroid/Thyroid/Retinoic Acid Gene Family, Keystone Symposium, Mar. 17-23, 1996 (Abstract).
Murray, B.S., et al., “Overexpression, purification, and functional analysis of the human androgen receptor protein,” Steroid/Thyroid/Retinoic Acid Gene Family, Keystone Symposium, Mar. 17-23, 1996 (Abstract).
Nardulli, A.M., et al., “Effects of estrogen receptor truncation and mutation on DNA bending and transcription activation,” Steroid/Thyroid/Retinoic Acid Gene Family, Keystone Symposium, Mar. 17-23, 1996 (Abstract).
Olayioye, M. A. Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res, 3: 385-389, 2001.
Pauletti, G., S. Dandekar, et al. (2000) “Assessment of methods for tissue-based detection of the HER-2
eu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry” J. Clin. Oncol. 18(21): 3651-64.
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B. E., Karandikar, M., Berman, K., and Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev, 22: 153-183, 2001.
Russo, J., Hu, Y. F., Yang, X., and Russo, I. H. Developmental, cellular, and molecular basis of human breast cancer [In Process Citation]. J Natl Cancer Inst Monogr, 27: 17-37, 2000.
Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M. H., and Yue, W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol, 80: 239-256, 2002.
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic . . . N Engl J Med, 344: 783-792, 2001.
Sliwkowski, M. X., Lofgren, J. A., Lewis, G. D., Hotaling, T. E., Fendly, B. M., and Fox, J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 26: 60-70, 1999.
Tremblay, G. B., Kunath, T., Bergeron, D., Lapointe, L., Champigny, C., Bader, J. A., Rossant, J., and Giguere, V. Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. Genes Dev, 15: 833-838, 2001.
Vanacker, J. M., Bonnelye, E., Chopin-Delannoy, S., Delmarre, C., Cavailles, V., and Laudet, V. Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha). Mol Endocrinol, 13: 764-773, 1999.
Vanacker, J. M., et al., Cell Growth Differ. 9:1007-1014, 1998.
Vanacker, J. M., Pettersson, K., Gustafsson, J. A., and Laudet, V. Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J, 18: 4270-4279, 1999.
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., and Press, M. Efficacy and safety of trastuzumab . . . J Clin Oncol, 20: 719-726, 2002.
Wiley, S. R., Kraus, R. J., Zuo, F., Murray, E. E., Loritz, K., and Mertz, J. E. (1993) Genes Dev. 7, 2206-2219.
Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R., Farndon, J., Cairns, J., Harris, A. L., and Horne, C. H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer, 65: 118-121, 1992.
Xie, W., Hong, H., Yang, N. N., Lin, R. J., Simon, C. M., Stallcup, M. R., and Evans, R. M. Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2. Mol Endocrinol, 13: 2151-2162, 1999.
Yang, C. and Chen, S. Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res, 59: 4519-4524, 1999.
Yang, C., et al., Cancer Res. 58:5695-5700, 1998.
Yang, N., et al., “Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter,” J. Biol. Chem. 271(10):5795-5804, 1996.
Zhang, X. and Yee, D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer, Breast Cancer Res, 2: 170-175, 2000.
Zhang, Z. and Teng, C. T. Estrogen receptor alpha and estrogen receptor-related receptor alpha1 compete for binding and coactivator. Mol Cell Endocrinol, 172: 223-233, 2001.
Lu, et al. Transcriptional Regulation of the Estrogen-inducible pS2 Breast Cancer Marker Gene by the ERR Family of Orphan Nuclear Receptors. Cancer Research 61, 6755-6761, Sep. 15, 2001.
Greenwald, Peter. Cancer Risk Factors for Selecting Cohorts for Large-Scale Chemoprevention Trials. J Cellular Biochemistry 25S, 29-36, 1996.
Yang, N. et al.
Ariazi Eric A.
Johnston Stephen D.
Kraus Richard J.
Mertz Janet E.
Quarles & Brady LLP
Sang Hong
Wisconsin Alumni Research Foundation
Yaen Christopher H
LandOfFree
Method of using estrogen-related receptor alpha (ERRα)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using estrogen-related receptor alpha (ERRα)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using estrogen-related receptor alpha (ERRα)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107016